Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
http://stockcharts.com/h-sc/ui?s=AMBS&p=D&b=5&g=0&id=p75813212303
It should be pretty obvious, but when you see how far outside the BBs the pps went yesterday, you see that $2.12 was a very nice trading entry point.
Not that I did that, but well, it was.
you won't like it but JN replied. For the most part, he now sounds like me with a couple of exceptions.
I think Eltoprazine is worth investigating. It is less than 50-50 to work long term.
ESS is a real product. If it is only worth $50 million then GC paid way too much for it. JN says it is worth $50 million.
MANF could be an answer for a couple of indications, but not others.
I can't disagree with the rest of it.
There are now three comments about ambs after that article, two are by me. Let's see if they get a response.
This is a seeking alpha article. He has written umpteen pieces on AMBS for Seeking alpha.
Now, I also asked JN a ? about AMBS at the end of that article. Let's see if he answers it. Of note, he already skipped over it and answered another question, pretty much the way I would have answered about AMBS. It is pretty interesting.
The absolute low pps for the Naz is $2 and it was just at $2.12.
GC's pay is pretty good as is the pay of JC. His investments in his own company's stock so far have been good sell indicators.
GC used to answer specific questions all the time. I don't think he has much to say about the stock price. That is another matter that I think he wishes was higher.
Bottom line, the need to triple the A/S is pressuring the pps. ESS-W should help the company in time. Navigating through the sharks is interesting.
It is nice to have a bunch of toys, but the georgetown test ( which no one at the company has mentioned recently ) msprecise - if it was everyone would be using it, Eltoprazine, and ESS are probably three too many toys for the company to handle at the moment.
I think that I am going to invest my life savings in this stock since it has tenative financing and no revenue.
Well, timing is also a factor. Given the pending vote to triple the available shares, the pps is going to a dollar, and everyeone knows it. If a non dilutive source of funding does not show up soon, all of the assets cannot be researched.
It only takes one, and ESS is the one. Sharks are in the water, and so it is up to the company to get a return on its ESS investment.
What is the total investment so far in ESS? It is up there, I know.
stopped out.
Well, this one is not a lie, it is just that things are not turning out the way GC hoped.
He was hoping for a juicy JV by now. of course, he was deluding himself in thinking that.
They do have ESS now and that will bring in some cash. They really need an ESS announcement.
Sichenzia Ross Friedman Ference LLP - The annual meeting has been adjourned to September 4, 2015 at 10:00 a.m. EDT at ,
661 Broadway, 32nd Floor, New York, New York 10006 - The beneficial stockholders may vote by internet at www.proxyvote.com, or by telephone at 800-454-8683.
That announcement is among the most bizarre I've seen in business. Of course, the other most bizarre anouncements have all been associated with AMBS.
http://www.barchart.com/chart.php?sym=AMBS&style=technical&template=&p=DO&d=M&sd=&ed=&size=M&log=0&t=BAR&v=1&g=1&evnt=1&late=1&o1=&o2=&o3=&sh=100&indicators=BBANDS%2820%2C2%2C10066431%2C3227936511%29%3BSTOSL%2814%2C3%2C16711680%2C153%29%3BSMACD%2812%2C26%2C9%2C16737792%2C10053375%2C13421721%29%3BRSIMOD%2814%2C0%2C100%2C10079487%2C10040064%29&chartindicator_4_code=BBANDS&chartindicator_4_param_0=20&chartindicator_4_param_1=2&chartindicator_4_param_2=10066431&chartindicator_4_param_3=3227936511&chartindicator_5_code=STOSL&chartindicator_5_param_0=14&chartindicator_5_param_1=3&chartindicator_5_param_2=16711680&chartindicator_5_param_3=153&chartindicator_6_code=SMACD&chartindicator_6_param_0=12&chartindicator_6_param_1=26&chartindicator_6_param_2=9&chartindicator_6_param_3=16737792&chartindicator_6_param_4=10053375&chartindicator_6_param_5=13421721&chartindicator_7_code=RSIMOD&chartindicator_7_param_0=14&chartindicator_7_param_1=0&chartindicator_7_param_2=100&chartindicator_7_param_3=10079487&chartindicator_7_param_4=10040064&addindicator=&submitted=1&fpage=&txtDate=#jump
We might even have a slow stochastic turning positive. That is a long link, but it works. The pps bounced off the BBs on the last five to 2.60. So yesterday's 2.9 may have been the retest.
The bet is on. So, that is that.
but this is a trading vehicle, and we have an MACD crossover, and an oversold condition and so it is a reasonable time to trade this stock.
http://stockcharts.com/h-sc/ui?s=AMBS&p=D&b=5&g=0&id=p35277391997
Let's try it at $3.38 ( 2.25 cents )
http://www.barchart.com/opinions/stocks/AMBS
of course, there is this. And that says, don't touch this.
except that is the exact topic on which MJFF disagreed with AMBS. ( See revised PR Nov 2012 by AMBS. )
AMBS is a great trading vehicle. It is bottoming, and getting ready for another great move. It has not bottomed yet.
Folks keep thinking that the pot of gold is tomorrow, and they get burned.
Just forget about that, trade AMBS and things will be happy on the AMBS message board.
This is an inflection point in their financing and trading. I have no idea how it is going to turn out. However, I am sure that AMBS will be a good trade at some point.
yes, I agree. But AMBS is run so badly, you wonder if they will wind up doing it.
I did say that ESS is product. I questioned AMBS ability to market it. There is a difference.
That is true. But if you listened to me, then you would not have gottened burned in the first place.
ESS is a real product. Things remain so tenuous with this company that you wonder a lot about their ability to bring it to market and make money off it.
i believe that the vote is ongoing. JP and company are keeping up with that.
I missed the point where they diluted themselves out of control of the company, that is pretty funny.
I waited to say this. Gee whiz, in the confusion, the board forgot to vote to keep itself in control of the company. I do not know what that means for the future but it is pretty interesting.
There was a time when they would show up to the meetings declare them over and then adjourn. ( more or less )
I re-checked the AMBS chart today and noted that the pps spiked down to $2.60 the other day. That is 1.7 cents. That is the interim low at the moment. In general, on a down trend the interim low is retested.
Of course, the pps is currently 2.21 cents.
So, at this level, all but those who bought in the summer and fall of 2012 are below water.
I wonder if there are any insider buys?
All of this is in the setting of the possession of a real asset, ESS.
huh, I stand corrected.
https://www.lawinsider.com/contracts/319f7KWSESlQkbmITFheRX/amarantus-bioscience/exec1566928/2013-04-04
Seriously, best read the voting power of the Series C shares. Then look up the other shares. Then re do the math.
How many votes does each series C share have?
1
2
10
300
1000
???
Well, the avg vol is only 50000 and the pps is $3. So it is not like anyone is trading a lot of money in and out of AMBS. Today they are at 30K+
There are different voting powers with the different levels of shares. The important shares can vote ten times their actual number.
More to the point, if you look up the voting power of the shares controlled by the board, you will see that they are in charge.
If you look up the voting power of those shares you will see that the board controls the company.
I was trying to say that I am not sure if the bottom is here or lower, but you would think that it is lower.
However, waiting for the chart to base is historically a good thing do to in general, and specifically with AMBS.
Let's be clear. $1 is the absolute bottom. Best to buy when the pps clearly bases.
Everyone is under water, and positive news is not doing much for the stock.
There is no rush to do anything.
At some point, if you think that they will get funding for ESS, then it is a buy, and you can average in. That could be now, depending on your assessment of the future.
The shares are already dropping because of that prospective dilution. The board controls the voting shares. This notion that your vote matters is only a small protest.
at $3.22 the pps is at 2.1 cents. So, the low of .007 cents is reasonable given the dilution ahead.
So, for now, a dollar should be the low. If it spikes down to a dollar I would buy in a minute.
This happened before you know. millions to hundreds of millions of shares to Billions of shares. Rinse and repeat times one.
They have a real issue also with the trading volume. It is too low.
It is one or the other, dilution or a JV deal. Let's see, where are those guarantees of a JV this year? What year is it? And for what compound/test are they going to make money?
it keeps changing.
In fairness, if they can get through to the funding, ESS should be a product. And it only takes one.
without the tripling of the a/s the company is going to run out of money.so they will bring it up again, next quarter, if needed. I suppose.
but if they are on the Naz the rules will be entirely different. So, maybe that is why they rushed this in at the last minute.
This is confusing, but well, that is AMBS for you.
I did not project this as a low. The absolute low would be about a dollar. You will know when the stock bases, it will be steady for about six weeks.
Now, since they are below $4, they will not make the Naz, on THAT day, they will sell off.
THAT will be a very good day to BUY. Whatever the price is.
After that, there is a ton of dilution to come, and so you have to continue to trade this.
Now, I could be wrong, since there are provisions to take stocks that are lower than this. This stock continues to behave like a penny stock, not like a Nazdaq stock. They just voted to triple the float.
Nazdaq stocks do not do that.
Now, knowing AMBS, they are probably trying to do a little of both, and slide by, but well, we will see if that works.
If somehow they wind up on the Naz, you miss a pop, but there are still great times to trade the stock.
Just wait for a very good base. Not a trade on a daily basis. There was a pretty good base at four cents and then it went to seven cents. Something like that.
I would bet they will fund it if it goes to phase III. The phase II is what they meany by wanting additional data. OTOH, if they were terribly hopeful of an indication for ELtoprazine for LID here, then they would have funded the Phase II.
I am thinking that it is going to be pretty hard for the pps to go below $4. There is a lot of interest in a $4 pps and so I am betting someone is going to buy.
AFTER they get in, the PPS will vary depending on the current climate.
IOW, normal prediction methods for pps and what not would not be pertinent, until after the NAZ uplist.
Then they will dilute the hell out of this again, and that will be that. When ESS can be sold it will, but it cannot for about a year at the earliest. ( more than likely )
and this is a phase II study, it is not a phase III study.
Someone asserted that dilutive financing was good. Well, that is never the case. Certainly, it is expected for a company at this stage, but well, the dilution in a couple of years went from 150 million shares to over a billion shares, and is now slated to quadruple from 8 million or so. ( The numbers may be off a little, the point is that the float has multiplied many times over. It seems like it is six, or seven, but it may be more than that. It is not less than that. I am sure.
Some companies continue to do that, and frankly, AMBS filed saying that they will have to quadruple the float from when they did the RS.
Again, the multiple may be three or actually, I think it is closer to five, but well, it is a lot.
That eplains the decrease in the share price. The prospect that more dilution is ahead, because the company said that it is ahead.
Now, ESS is a real product, however, the results will not be in for many years.
Estimated Enrollment: 10
Study Start Date: July 2015
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: July 2019 (Final data collection date for primary outcome measure)
https://clinicaltrials.gov/ct2/show/NCT01655407
So, you never know, until the trial is halted for obvious success, or completed, or the asset is sold, if ESS will bring in cash.
I tend to think the study will be positive, and at some point, because of that asset, and only that asset, AMBS will be a buy.
Why on earth they anounced a tripling of the A/S BEFORE uplisting is probably due to the rules, but it was not a good idea for the pps.
This may be the bottom, certainly, it is around here somewhere. But there are many years of trial before the end of this saga.
Now, you know what will boost the pps, but well, those things haven't happened, and if they could happen then they would because folks are looking forward to making money from the Naz.
The SOONEST someone will buy in ESS is when they see it work. Now, burns are not exactly something that you can double blind. It is out there for you to see. And so, if I were a pharma with money, I would keep track of the study.
It will not take that long for folks to get a clinical impression of its efficacy.
Bottom line, the competition should not be as good as ESS, because it is a full thickness graft for those who need full thickness grafts and do not have enough extra skin to move around, or stretch out, and then move around, because it is gone.
This was a good purchase, but the timing is bad, and the financing is massively dilutive.
GC bought WAY too many things at once. And over hyped them to the point of lying about everything but this product.
That said, it only takes one product.
long term investors are almost all under water, and so their smiles cannot be seen, or they have drowned.
A nice buying opportunity is coming up however.